Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent P2-VP8 Rotavirus Vaccine Challenge Study
NCT04658914Phase 2Completed
- Sponsor
- Center for Infectious Disease Research in Zambia
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of trivalent P2-VP8 subunit rotavirus vaccine in rotavirus infection, sponsored by Center for Infectious Disease Research in Zambia. Started Apr 2021; status: completed.
02
Drugs
trivalent P2-VP8 subunit rotavirus vaccine
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT04658914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658914.